In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 226 to 250 of 441

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]	Technology appraisal guidance	TBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]	Technology appraisal guidance	2 December 2026
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]	Technology appraisal guidance	TBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]	Technology appraisal guidance	TBC
Managing common infections - antimicrobial prescribing guidelines	NICE guideline	TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]	Technology appraisal guidance	TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]	Technology appraisal guidance	TBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]	Technology appraisal guidance	TBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]	Technology appraisal guidance	TBC
Melanoma (metastatic) - talimogene laherparepvec [ID508]	Technology appraisal guidance	28 September 2016
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver	Interventional procedures guidance	TBC
Mental health guidelines	NICE guideline	TBC
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237	Technology appraisal guidance	6 August 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	NICE guideline	2 December 2026
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]	Technology appraisal guidance	TBC
Middle meningeal artery embolisation for chronic subdural haematomas	Interventional procedures guidance	TBC
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]	Technology appraisal guidance	7 May 2026
Monofocal intraocular lenses for cataract surgery (provisional title)	Health technology evaluation	TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]	Technology appraisal guidance	TBC
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor	Interventional procedures guidance	TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]	Technology appraisal guidance	TBC

Results per page

10
25
50
All